DelveInsight’s “Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Myeloid Leukemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Acute Myeloid Leukemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Myeloid Leukemia: An Overview
Acute myeloid leukemia (AML) (also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and other tissues. Acute Myeloid Leukemia can involve tissues outside the bone marrow and blood, including lymph nodes, the brain, skin, and other body parts.
The most prevalent form of leukemia in adults is Acute Myeloid Leukemia, which makes up around 80% of all cases. It is characterized by ineffective erythropoiesis, and bone marrow failure is caused by the clonal growth of immature “blast cells” in the peripheral blood and bone marrow. AML is the most common acute leukemia in adults and primarily affects older people, with a median age of diagnosis of ~67 years. The chromosomal anomalies that each patient possesses are often exclusive to them. The frequency of anomalies is greater as people age.
Acute Myeloid Leukemia Market Key Facts
Acute Myeloid Leukemia is one of the most common types of leukemia in adults. Still, Acute Myeloid Leukemia is fairly rare overall, accounting for only about 1% of all cancers.
According to Cancer Research UK, Acute Myeloid Leukemia incidence is strongly related to age, with the highest incidence rates being in older people. In the UK in 2016-2018, on average, each year, more than 4 in 10 new cases (42%) were in people aged 75 and over. Age-specific incidence rates rise gradually from birth, rise steadily from around age 50-54, rise more steeply from age 60-64 and drop in the oldest age groups.
According to Miyamoto & Minami (2019), the annual incidence of Acute Myeloid Leukemia in Japan is 5.6 per 100,000. The annual incidence of Acute Myeloid Leukemia has increased with population age, reaching up to 10–17 cases per 100,000 patients who are over 69 years old, compared to 0.6–6 instances per 100,000 patients in less than 70 years old. As a result, individuals with Acute Myeloid Leukemia tend to be older than 69 years old.
According to the Surveillance, Epidemiology, and End Results (SEER) study program, the rate of new cases of acute myeloid leukemia was 4.3 per 100,000 men and women per year in the United States. The death rate was 2.7 per 100,000 men and women per year. These rates are age-adjusted and based on 2014–2018 cases and 2015–2019 deaths.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Acute Myeloid Leukemia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Acute Myeloid Leukemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Myeloid Leukemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Acute Myeloid Leukemia (AML) Epidemiology, Segmented by –
Total Incident Cases of Acute Myeloid Leukemia in the 7MM [2019–2032]
Gender-specific Cases of Acute Myeloid Leukemia in the 7MM [2019–2032]
Age-specific Cases of Acute Myeloid Leukemia in the 7MM [2019–2032]
Mutation-specific Cases of Acute Myeloid Leukemia in the 7MM [2019–2032]
Acute Myeloid Leukemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Myeloid Leukemia market or expected to be launched during the study period. The analysis covers the Acute Myeloid Leukemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Myeloid Leukemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Myeloid Leukemia Market Will Evolve and Grow by 2032 @
Acute Myeloid Leukemia Therapeutics Analysis
Several unmet needs exist in Acute Myeloid Leukemia. For instance, more-effective, less-toxic treatments are urgently needed because many patients with Acute Myeloid Leukemia are not candidates for standard induction therapy. Acute Myeloid Leukemia is also characterized by high rates of relapsed/refractory disease. Other unmet needs center on the poor quality of life from disease- and therapy-related toxicities. With several unmet needs, the therapeutics space is quite active, with a robust pipeline of drugs in clinical development, which is likely to boost the market growth in the coming years.
There are approx. 260+ key companies which are developing Acute Myeloid Leukemia therapies. Currently, Gamida Cell has its Acute Myeloid Leukemia drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Acute Myeloid Leukemia (AML) Therapeutics Market Include:
Pfizer, Bristol Myers Squibb, Agios Pharmaceuticals, Abbvie, Jazz Pharmaceuticals. Astellas Pharma, Novartis Oncology, Daiichi Sankyo, AstraZeneca, Astex Pharmaceuticals, Inc., Chimerix, Takeda, Rafael Pharmaceuticals Inc., Delta-Fly Pharma, GlycoMimetics Incorporated, BerGenBio ASA, MacroGenics, Syndax Pharmaceuticals, Arog Pharmaceuticals, Forma Therapeutics, Sellas Life Sciences Group, Actinium Pharmaceuticals, Clear Creek Bio Inc., CellCentric Ltd., Biosight Ltd., Curis, Inc., NexImmune Inc., Immunomedics, Inc., and many others.
Acute Myeloid Leukemia (AML) Drugs Covered in the Report Include:
Omidubicel: Gamida Cell
ALT 803: ImmunityBio
BPX-501: Bellicum Pharmaceuticals
Dociparstat Sodium (Chimerix
Crenolanib besylate: Arog pharmaceuticals
JSP191: Jasper therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Myeloid Leukemia Competitive Intelligence Analysis
4. Acute Myeloid Leukemia Market Overview at a Glance
5. Acute Myeloid Leukemia Disease Background and Overview
6. Acute Myeloid Leukemia Patient Journey
7. Acute Myeloid Leukemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Acute Myeloid Leukemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Myeloid Leukemia Unmet Needs
10. Key Endpoints of Acute Myeloid Leukemia Treatment
11. Acute Myeloid Leukemia Marketed Products
12. Acute Myeloid Leukemia Emerging Drugs and Latest Therapeutic Advances
13. Acute Myeloid Leukemia Seven Major Market Analysis
14. Attribute Analysis
15. Acute Myeloid Leukemia Market Outlook (In US, EU5, and Japan)
16. Acute Myeloid Leukemia Access and Reimbursement Overview
17. KOL Views on the Acute Myeloid Leukemia Market
18. Acute Myeloid Leukemia Market Drivers
19. Acute Myeloid Leukemia Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Other Trending Healthcare Reports By DelveInsight
“Acute Myeloid Leukemia Pipeline Insight, 2023,” report provides comprehensive insights about 260+ companies and 260+ drugs in the Acute Myeloid Leukemia pipeline landscape. It covers the pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical stage products by stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States